@article{HBSN22303,
author = {Mari Masuda},
title = {Hunting hidden pieces of signaling pathways in hepatocellular carcinoma},
journal = {Hepatobiliary Surgery and Nutrition},
volume = {8},
number = {1},
year = {2018},
keywords = {},
abstract = {Advanced hepatocellular carcinoma (HCC) has a poor prognosis with limited treatment options. During the last decade, sorafenib, a multi-tyrosine kinase inhibitor (TKI), has been the only available systemic agent for first-line treatment of unresectable HCC (1). Recently, another multi-TKI, lenvatinib, was added to the list of first-line treatment alternatives based on the results of the phase III RREFLECT trial.},
issn = {2304-389X}, url = {https://hbsn.amegroups.org/article/view/22303}
}